Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types

Abstract

Cervical cancer is the third most common cancer in women worldwide and often affects women under 40 years of age with young families. Vaccination against HPV is a major advancement, as it offers primary prevention against the infectious agent that is the main cause of the disease. The bivalent AS04-adjuvanted prophylactic HPV vaccine provides high efficacy against disease associated with HPV 16 and 18, as well as significant cross-protection against some HPV types not included in the vaccine. Protection against HPV 45 may be particularly important, as it is relatively more common in adenocarcinoma. The vaccine’s antibody response profile suggests a long duration of immunity. Safety data have been reassuring, which is not unexpected, given that the vaccine is composed of virus-like particles, rather than being a live-virus vaccine.

Keywords::

• bivalent vaccine
• Cervarix®
• cervical cancer
• HPV vaccine
• human papillomavirus

Financial & competing interests disclosure

A Szarewski has received conference sponsorship, honoraria and consultancy fees from both GlaxoSmithKline and Merck, Sharp and Dohme. She is also an investigator in two GlaxoSmithKline Phase III HPV 16/18 vaccine trials. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.